Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04790279 · ClinicalTrials.gov registry record · Phase 4

Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension

A Phase 4 study, sponsored by Prisma Health-Upstate.

Completed
Registry status
Phase 4
Development phase
175
Enrollment target

NCT04790279: Completed Phase 4 study, sponsored by Prisma Health-Upstate.

NCT04790279 is a Phase 4 study that has completed, run by Prisma Health-Upstate. The registered enrollment target is 175 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04790279, a Phase 4 study, has completed, sponsored by Prisma Health-Upstate.

COMPLETED
Registry status
Phase 4
Development phase
175 participants
Enrollment target

Study Summary

A significant number of pregnancies are complicated by hypertensive disorders. Hypertension often worsens in the postpartum period and many women need started on medications. Currently, recommended medications for blood pressure management in pregnant and postpartum women are limited, with labetalol and nifedipine ER being the most commonly used medications. While these medications are both effective, they are not without limitations. Amlodipine is a medication in the same class as nifedipine ER. It is a first-line antihypertensive in the general population. It tends to have less side effects than nifedipine ER. It has not been studied specifically in postpartum women. The purpose of this study is to determine if amlodipine is noninferior to nifedipine ER in managing hypertension in the postpartum period.

Primary Outcome

length of stay from delivery until discharge

Interventions

  • DRUG Amlodipine
  • DRUG NIFEdipine ER

Trial Details

FieldValue
Enrollment Target 175 participants
Start Date 2021-04-09
Est. Completion 2023-01-25
Phase Phase 4
Prisma Health-Upstate

67 total trials

What the finished NCT04790279 record still lists

NCT04790279 is an interventional study that assigns participants to a tested intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (66% lower).

The record links to 0 conditions, and to 2 interventions - of which Amlodipine is the first listed.

NCT04790279 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04790279 about?

NCT04790279 is a clinical study titled "Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension". A significant number of pregnancies are complicated by hypertensive disorders. Hypertension often worsens in the postpartum period and many women need started on medications. Currently, recommended medications for blood pressure management in pregnant and postpartum women are limited, with labetalol...

What is the current status of trial NCT04790279?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 175 participants. The study started on 2021-04-09. Estimated completion is 2023-01-25.

What interventions are being tested in trial NCT04790279?

The interventions under investigation include: Amlodipine (DRUG), NIFEdipine ER (DRUG).

Who is sponsoring clinical trial NCT04790279?

This trial is sponsored by Prisma Health-Upstate, which has 67 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04790279's enrollment target sits among peer trials

175 478th of 2000 higher than 1,521 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04722341 · 175 participants · NA

    Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators

  • NCT05094037 · 175 participants · NA

    Orthotic Treatment of Diabetic Foot Ulcers

  • NCT05165745 · 175 participants · NA

    Stick2PrEP Cisgender Women and Trans Individuals

  • NCT05312255 · 175 participants · NA

    Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04790279, the US trial registry maintained by the National Library of Medicine. NCT04790279 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.